[HTML][HTML] Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
C Fu, L Yu, Y Miao, X Liu, Z Yu, M Wei - Acta Pharmaceutica Sinica B, 2023 - Elsevier
Peptide–drug conjugates (PDCs) are the next generation of targeted therapeutics drug after
antibody–drug conjugates (ADCs), with the core benefits of enhanced cellular permeability …
antibody–drug conjugates (ADCs), with the core benefits of enhanced cellular permeability …
Tumor-Homing Peptides as Crucial Component of Magnetic-Based Delivery Systems: Recent Developments and Pharmacoeconomical Perspective
S Milewska, A Sadowska, N Stefaniuk… - International Journal of …, 2024 - mdpi.com
According to data from the World Health Organization (WHO), cancer is considered to be
one of the leading causes of death worldwide, and new therapeutic approaches, especially …
one of the leading causes of death worldwide, and new therapeutic approaches, especially …
Targeting the gastrin-releasing peptide receptor (GRP-R) in cancer therapy: Development of bombesin-based peptide–drug conjugates
J Gomena, B Vári, R Oláh-Szabó, B Biri-Kovács… - International Journal of …, 2023 - mdpi.com
Targeted tumour therapy has proved to be an efficient alternative to overcome the limitations
of conventional chemotherapy. Among several receptors upregulated in cancer cells, the …
of conventional chemotherapy. Among several receptors upregulated in cancer cells, the …
Oxime-Linked Peptide–Daunomycin Conjugates as Good Tools for Selection of Suitable Homing Devices in Targeted Tumor Therapy: An Overview
Chemotherapy is still one of the main therapeutic approaches in cancer therapy.
Nevertheless, its poor selectivity causes severe toxic side effects that, together with the …
Nevertheless, its poor selectivity causes severe toxic side effects that, together with the …
Influence of the Drug Position on Bioactivity in Angiopep-2—Daunomycin Conjugates
The blood–brain barrier (BBB) is a semipermeable system, and, therefore, most of the active
substances are poorly transported through this barrier, resulting in decreased therapeutic …
substances are poorly transported through this barrier, resulting in decreased therapeutic …
Structural Characterization of Daunomycin-Peptide Conjugates by Various Tandem Mass Spectrometric Techniques
The use of peptide-drug conjugates has generated wide interest as targeted antitumor
therapeutics. The anthracycline antibiotic, daunomycin, is a widely used anticancer agent …
therapeutics. The anthracycline antibiotic, daunomycin, is a widely used anticancer agent …
[PDF][PDF] Review, Bioconjugates: A New Class of Therapeutics for Cancer Treatment
Bioconjugates represent a novel class of therapeutics that offer promise in the treatment of
cancer. These compounds are formed by combining a targeting molecule, such as an …
cancer. These compounds are formed by combining a targeting molecule, such as an …
[PDF][PDF] Discovery and biosynthesis of the redox cofactor mycofactocin
LA Peña Ortiz - d-nb.info
Discovery and biosynthesis of the redox cofactor mycofactocin Page 1 DISCOVERY AND
BIOSYNTHESIS OF THE REDOX COFACTOR MYCOFACTOCIN Dissertation zur Erlangung des …
BIOSYNTHESIS OF THE REDOX COFACTOR MYCOFACTOCIN Dissertation zur Erlangung des …
[PDF][PDF] Effect of ionization conditions in electrospray ionization mass spectrometry of daunorubicin-tuftsin peptide conjugates
Daunomycin (Dau) is an anthracycline anticancer antibiotic that can bind to the DNA in the
nucleus and can inhibit the topoisomerase IIα enzyme. 1 The use of daunorubicin in clinical …
nucleus and can inhibit the topoisomerase IIα enzyme. 1 The use of daunorubicin in clinical …
[PDF][PDF] Tandem mass spectrometry of daunorubicin-containing peptide conjugates
Daunomycin (Dau) is an anthracycline anticancer drug, commonly used for the treatment of
several types of leukemia. 1 It consists of an anthraquinone aglycon moiety and a …
several types of leukemia. 1 It consists of an anthraquinone aglycon moiety and a …